Table 3

Antigens discriminating between sustained and transient responders
Part A Antigens with significantly higher expression in SR compared to TR
Antigen
 Baseline
 TimePoint2
 TimePoint3
 TimePoint4
 P valuea
CD11aSRb
 153 ± 28.1
 152 ± 19.2
 141 ± 25
 157 ± 24.4
 0.002
CD11aTRc
 130 ± 17.2
 123 ± 17
 124 ± 14.7
 136 ± 9.6
CD29SR
 145 ± 25.5
 151 ± 14.3
 147 ± 20.3
 160 ± 23.1
 0.001
CD29TR
 120 ± 35.5
 113 ± 10.5
 129 ± 12.8
 129 ± 16.2
CD38SR
 119 ± 32.4
 123 ± 13.7
 131 ± 21.3
 138 ± 19
 0.045
CD38TR
 105 ± 19.3
 106 ± 28.4
 109 ± 16.4
 116 ± 20.1
CD45ROSR
 107 ± 38.8
 107 ± 17.9
 105 ± 24.2
 108 ± 19.2
 0.003
CD45ROTR
 72 ± 18.7
 75 ± 17.5
 64 ± 27.1
 73 ± 30.5
CD52SR
 127 ± 40.5
 136 ± 15.9
 136 ± 22.5
 139 ± 10.9
 0.048
CD52TR
 112 ± 25.1
 111 ± 19.6
 114 ± 21.3
 118 ± 19.3
Part B Antigens with significantly lower expression in SR compared to TR
Antigen
 Baseline
 TimePoint2
 TimePoint3
 TimePoint4
 P valuea
CD56SRb
 0
 17
 17
 17
 0.047
CD56TRc
 17
 33
 33
 83
CD57SR
 33
 50
 17
 50
 0.022
CD57TR
 83
 67
 83
 83
CD62ESR
 33
 67
 50
 83
 0.012
CD62ETR
 83
 83
 100
 100
CD64SR
 67
 83
 83
 67
 0.012
CD64TR
 100
 100
 83
 100
CD33SR
 17
 17
 50
 50
 < 0.001
CD33TR
 100
 100
 83
 83

Part A: Data presented are dot intensities, shown by mean ± standard deviation.

Part B: Data are presented as the percentage of patient samples showing detectable expression level of the corresponding antigens in each patient group since some samples had below detection expression levels for some antigens. The cut off value of 10 was used to identify detectable expression levels.

a Level of significance of the group parameter in a repeated measure mixed model analysis of variance was used to assess the difference in values between groups.

b SR: sustained responder group.

c TR: transient responder group.

Wu et al. Retrovirology 2008 5:24   doi:10.1186/1742-4690-5-24